VFA
NNVC icon

Virtus Fund Advisers’s NanoViricides NNVC Stock Holding History

Virtus Fund Advisers’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-171
Closed -$14K – 1657
2014
Q2 		$14K Buy
+171
New +$12.1K ﹤0.01% 2636

Other funds holding NNVC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Virtus Fund Advisers's NNVC Position: Q3 2014 in Review

Virtus Fund Advisers sold out of NanoViricides (NNVC) in Q3 2014, closing a stake of 171 shares — an estimated $14K sold.

Virtus Fund Advisers first reported a position in NNVC in Q2 2014 and held it in 1 quarter. The position peaked at $14K in Q2 2014. 53 funds tracked by Wall St. Rank hold NNVC as of Q3 2014.

  • Virtus Fund Advisers reported no remaining NanoViricides position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 171 NanoViricides shares in Q3 2014, an estimated $14K.
  • Virtus Fund Advisers first reported a position in NanoViricides in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's NanoViricides position peaked at $14K in Q2 2014.
  • 53 funds tracked by Wall St. Rank held NanoViricides as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.